This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Evans, S. M. Articles by Wilson, D. F. Search for Related Content PubMed PubMed Citation Articles by Evans, S. M. Articles by Wilson, D. F.

Tamoxifen Induces Hypoxia in MCF-7 Xenografts¹

Departments of Clinical Studies [S. M. E., K. M. L.] and Pathology [T. V. W.], School of Veterinary Medicine, and Departments of Radiation Oncology [C. J. K., W. T. J.] and Biochemistry and Biophysics [D. F. W.], School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104

Tamoxifen is widely used as an adjunct therapy for breast cancer. We hypothesized that hypoxia develops in tumors as a result of tamoxifen treatment because tamoxifen has been reported to be antiangiogenic and thrombogenic. MCF-7 breast tumors were grown under estrogenic stimulation in 4-6-week-old CD-1 nu/nu female mice. When the tumors were approximately 5 mm in diameter, 17ß-estradiol pellets were replaced with either placebo or tamoxifen-containing pellets. Two days later, tissue oxygenation was measured using immunohistochemical detection of binding of the 2-nitroimidazole EF5. Intravascular oxygen partial pressures were measured noninvasively by oxygen-dependent quenching of phosphorescence of an injected dye that is excited by light pulses. Tamoxifen treatment increased hypoxia in the tumors, as measured by EF5 binding (P = 0.01 by Mann-Whitney test). This observation was not dependent on the presence of tamoxifen-induced necrosis. Intravascular oxygen partial pressures were lower in tumors relative to surrounding normal tissue in tamoxifen-treated tumors as compared to placebo-treated tumors. In vitro, tamoxifen did not modify the oxygen-dependent metabolism of EF5, indicating that the increased EF5 binding in tamoxifen-treated tumors reflects a physiological decrease in tissue oxygenation. The clinical significance of these observations is discussed in the context of the sequencing of tamoxifen with other therapies, and in light of recent data suggesting that hypoxia may be associated with genetic changes resulting in a more aggressive tumor phenotype.

¹ Supported by a grant from the University of Pennsylvania Research Foundation.

² To whom requests for reprints should be addressed, at University of Pennsylvania, 195 John Morgan Building, 36th and Hamilton Walk, Philadelphia, PA 19104. Fax: (215) 898-0090; E-mail: syndevans@vet.upenn.edu.

Received 7/16/97. Accepted 9/22/97.

This article has been cited by other articles:

				W. H. Dragowska, C. Warburton, D. T.T. Yapp, A. I. Minchinton, Y. Hu, D. N. Waterhouse, K. Gelmon, K. Skov, J. Woo, D. Masin, et al. HER-2/neu Overexpression Increases the Viable Hypoxic Cell Population within Solid Tumors without Causing Changes in Tumor Vascularization Mol. Cancer Res., November 1, 2004; 2(11): 606 - 619. [Abstract] [Full Text] [PDF]

				K. L. Blackwell, Z. A. Haroon, S. Shan, W. Saito, G. Broadwater, C. S. Greenberg, and M. W. Dewhirst Tamoxifen Inhibits Angiogenesis in Estrogen Receptor-negative Animal Models Clin. Cancer Res., November 1, 2000; 6(11): 4359 - 4364. [Abstract] [Full Text] [PDF]

				T. M. Busch, S. M. Hahn, S. M. Evans, and C. J. Koch Depletion of Tumor Oxygenation during Photodynamic Therapy: Detection by the Hypoxia Marker EF3 [2-(2-Nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide] Cancer Res., May 1, 2000; 60(10): 2636 - 2642. [Abstract] [Full Text]

				R. Davies, T. W. Gant, L. L. Smith, and J. A. Styles Tamoxifen induces G:C->T:A mutations in the cII gene in the liver of lambda/lacI transgenic rats but not at 5'-CpG-3' dinucleotide sequences as found in the lacI transgene Carcinogenesis, July 1, 1999; 20(7): 1351 - 1356. [Abstract] [Full Text] [PDF]